Search Results
Your search for ,had matches 18604 pages
Showing 12751 - 12800Addressing the Significant Disparities and Barriers to Health Care Experienced by LGBT Cancer Survivors
In 2011, the Institute of Medicine (IOM) published its landmark report “The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding,” which recognized the scarcity of research in lesbian, gay, bisexual, and transgender (LGBT) individuals and the...
Venetoclax Produces High Response Rate in Relapsed or Refractory CLL With 17p Deletion
In a pivotal phase II study reported in The Lancet Oncology, Stephan Stilgenbauer, MD, of Ulm University, Germany, and colleagues found that the BCL2 inhibitor venetoclax (ABT-199) produced a high response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p ...
Study Examines Global Trends in Ovarian Cancer Mortality Rates
Deaths from ovarian cancer fell worldwide between 2002 and 2012, and are predicted to continue to decline in the United States, European Union (EU) and Japan by 2020, according to new research published by Malvezzi et al in Annals of Oncology. The main reason is the use of oral contraceptives and...
DNA Methylation Assay May Improve Diagnosis of Cancer of an Unknown Primary
As reported in The Lancet Oncology, Moran et al developed a classifier of cancer type based on microarray DNA methylation signatures (EPICUP assay), which has showed promise in diagnosing cancers of an unknown primary. Study Details The tumor type classifier was developed in a training set of...
Nivolumab in Recurrent Classical Hodgkin Lymphoma: Refreshingly Supportive Data
It is commonly said that if something is too good to be true, it usually is. It is therefore quite refreshing when really good results are replicated in a subsequent study. As reported in The Lancet Oncology by Younes et al1 and reviewed in this issue of The ASCO Post, a phase II trial of...
Nivolumab Achieves Response in Most Patients With Classical Hodgkin Lymphoma After ASCT and Brentuximab Vedotin
In a phase II trial reported in The Lancet Oncology by Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, treatment with the anti–PD-1 (programmed cell death protein 1) immune checkpoint inhibitor nivolumab (Opdivo) produced response in two-thirds of patients with...
Weight Watchers and the American Cancer Society Launch Initiative to Support Holistic Health for Breast Cancer Survivors
Weight Watchers International, Inc, has launched Project LIFT—Live Inspired, Fight Together—a new movement, in collaboration with the American Cancer Society, to inspire and guide breast cancer survivors with free resources focused on tackling the unexpected weight gain that can follow breast...
Multitude of Mentors Help Shape an Illustrious Career in Oncology
Sumanta K. Pal, MD, has had a longer career in oncology than many other colleagues his age. Perhaps the reason for that may center on his starting college at the age 13 and medical school at the age of 17. Today this internationally recognized leader in genitourinary cancers is Assistant Professor ...
Management of Merkel Cell Carcinoma
A recent report regarding pembrolizumab (Keytruda) for advanced Merkel cell carcinoma ushered in a more optimistic era in the treatment of this rare but often lethal skin cancer.1 The ASCO Post spoke with one of the field’s leaders, Paul Nghiem, MD, PhD—the first author of the study—about the...
Use of Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Therapy
On August 5, 2016, pembrolizumab (Keytruda) was granted accelerated approval for treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma and disease progression on or after platinum-containing chemotherapy.1,2 As a condition of the accelerated approval, Merck is...
Effect of Radiosurgery Alone vs With Whole-Brain Radiotherapy on Cognitive Function in Patients With Brain Metastases
Physicians from Carolinas HealthCare System’s Neurosciences Institute and Levine Cancer Institute are among the authors of a recent study published by Brown et al in JAMA.1 The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery alone, compared...
ASCO 2016: Geriatric Oncology Highlights
Clinical trials focused on older adults with cancer were featured prominently at the 2016 ASCO Annual Meeting. There was a plenary session in glioblastoma, a clinical symposium on immunotherapy, and multiple educational lectures highlighting the growing literature and unique challenges in the...
Interim PET-Adapted Treatment in Advanced Hodgkin Lymphoma
The ability to cure a majority of patients with advanced Hodgkin lymphoma is one of the major milestones of success in the combination chemotherapy era. It has been over 40 years since Bonadonna and colleagues in Milan developed the ABVD regimen (doxorubicin, bleomycin, vinblastine, and...
Continued ABVD vs Omission of Bleomycin (AVD) After Negative Imaging Findings in Advanced Hodgkin Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Peter Johnson, MD, of the Cancer Research UK Centre, University of Southampton, and colleagues found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs omission of bleomycin (AVD) after...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer...
Posttreatment Problems Surveyed in African American Breast Cancer Survivors
Although there is some overlap, past research has shown that the challenges faced by African American breast cancer survivors differ somewhat from Caucasian women. But the studies that demonstrated difference were not designed to explore those challenges in depth. Now new research from Thomas...
Study Finds Minimal Residual Disease Assessment Improves Prediction of Outcome in CLL Responders
Assessment of minimal residual disease was associated with improved prediction of outcome in responders, as well as complete responders, in patients with chronic lymphocytic leukemia (CLL) who respond to treatment. Kovacs et al reported these findings, which are based on an analysis of two phase...
Hypofractionated Radiotherapy for Localized Prostate Cancer: A New Standard of Care?
For at least the past quarter of a century, radiobiologists and radiation oncologists have debated the role of hypofractionation (fewer total fractions with a higher dose per fraction) for prostate cancer. The debate stems from the unique radiobiology of prostate cancer and the best means to...
Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma
In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...
For High-Grade and Aggressive Non-Hodgkin Lymphomas, Treat Adults Like Children
Outcomes for adults with high-grade and aggressive non-Hodgkin lymphomas (NHLs) appear to be better when these patients are treated with pediatric-inspired protocols, according to Mitchell S. Cairo, MD, Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria...
Predictors of Readmission in Patients Requiring Free Tissue Reconstruction for Head and Neck Cancer
Certain factors increase the risk of unplanned readmission in the month after head and neck cancer resection requiring free tissue reconstruction, finds an analysis of data from the National Surgical Quality Improvement Program (NSQIP) of the American College of Surgeons.1 Nearly 1 in 10 patients...
Good Showing for Trastuzumab/Docetaxel Combination Against Salivary Gland Carcinoma
The combination of trastuzumab (Herceptin) and docetaxel seems to be highly active in patients with unresectable advanced HER2-positive salivary gland carcinoma of the ductal subtype, according to interim data from an open-label, single-arm phase II trial.1 More than two-thirds of patients had a...
Benefits Seen From Extending Steroids After Transoral Robotic Surgery for Head and Neck Cancer
Patients undergoing transoral robotic surgery for head and neck cancer may experience improvements in some outcomes when given an extended course of corticosteroids, finds a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Relative to peers given...
Nerve Stimulation During Oncologic Neck Dissection May Help to Preserve Shoulder Function
Electrical stimulation of the spinal accessory nerve during neck dissection for head and neck cancer may reduce the development of shoulder dysfunction, according to a double-blind randomized controlled trial.1 A year after surgery, patients given intraoperative electrical stimulation had...
Use of Lugol’s Iodine Stain May Reduce the Need for Repeat Resection of Oral and Oropharyngeal Cancers
By identifying residual dysplasia in the tumor bed, Lugol’s iodine staining may improve pathologic outcomes with resection of oral and oropharyngeal cancers, according to interim findings of a UK randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1...
Is Obesity a Prognostic Factor for Improved Survival in Metastatic Renal Cell Carcinoma?
In a study investigating the clinical and biologic effects of body mass index on treatment outcomes in patients with metastatic renal cell carcinoma, Albiges et al found that obese patients treated with targeted therapy had improved survival and progression-free survival compared with patients with ...
Palliative Care 2016: 'Mystery Shopper' Study Finds Barriers to Accessing Palliative Care Services at Major Cancer Centers
A team of researchers, using a novel approach, found that while many cancer centers offer palliative and supportive care services, patients may face challenges when trying to access them. The study showed that expanding awareness and education to patient-facing cancer center employees about such...
Palliative Care 2016: Early Palliative Care Improves Coping, Quality of Life for Patients With Incurable Cancers
A randomized clinical trial found that introducing palliative care shortly after a diagnosis of certain metastatic cancers greatly increases a patient’s coping abilities, as well as overall quality of life. Researchers also found that early integration of palliative care results in an...
Patients With Cancer May Be at Heightened Risk of Injuries During Diagnostic Process
Patients with cancer have heightened risks of unintentional and intentional injuries during the diagnostic process, revealed findings from a large study published by Shen et al in The BMJ. A range of injuries are common, and some are potentially life-threatening, the study showed. The authors...
Autologous Stem Cell Transplant May Age Immune Cells as Much as 30 Years
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers, by tracking p16INK4a, a molecular marker that has been shown to increase in white blood cells as people age, have uncovered clues suggesting that stem cell transplant is linked to a marked increase in the...
Early Relapse in Follicular Lymphoma: Clinical Trial Data May Guide Management Decisions
Approximately 20% of patients with follicular lymphoma will relapse within 2 years of diagnosis. Although the optimal management of these patients has not been established, clinicians may be guided by data from recent clinical trials, according to Nathan H. Fowler, MD, Associate Professor and...
Higher Baseline Metabolic Tumor Volume May Predict Poorer Outcome in Patients With High Tumor Burden Follicular Lymphoma
In a pooled analysis reported in the Journal of Clinical Oncology, Meignan et al found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG PET-CT) was associated with poorer outcome in patients...
PSA-Based Computational Model Predicts Time to Relapse After Prostate Cancer Surgery
Approximately one in four patients who undergo radical prostatectomy experience a cancer recurrence. Now a study by Stura et al investigating a prostate-specific antigen (PSA)-based computational model that uses four consecutive postsurgical PSA values has found the mathematical model to be highly...
Retinoic Acid May Suppress Colorectal Cancer Development
Retinoic acid may play a critical role in suppressing colorectal cancer in mice and humans, according to researchers at the Stanford University School of Medicine. Mice with the cancer have lower-than-normal levels of the metabolite in their gut, the researchers found. Furthermore, colorectal...
Outpatient Bloodstream Infections Costly for Pediatric Stem Cell Transplant and Cancer Patients
Pediatric stem cell transplant and cancer patients often are discharged from the hospital with an external central venous line for medications that parents or other caregivers must clean and flush daily to avoid potentially life-threatening infections. If an outpatient develops a bloodstream...
Psychosocial Adjustment, Breast Cancer–Specific Distress in Adolescent Girls From BRCA1/2-Positive and Breast Cancer Families
Adolescent girls from BRCA1/2-positive and breast cancer families appear to have higher self-esteem and similar psychosocial adjustment compared with their peers but experience greater breast cancer–specific distress and perceived risk of breast cancer. Bradbury et al reported these findings...
Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In the phase III CASTOR trial reported in The New England Journal of Medicine, Palumbo et al found that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone markedly improved progression-free survival among patients with relapsed or relapsed and refractory...
Epigenetic Dysregulation of MicroRNA-34A Identified in TP53-Related Cancer Risk
In a genome-wide DNA-methylation analysis to identify genes implicated in Li-Fraumeni syndrome, Samuel et al found a significant association of loss-of-function <em>TP53</em> mutations with differential methylation at the locus encoding microRNA-34A (miR-34A). The study was reported in...
Study Finds Chemotherapy May Be Avoidable in Women With Early Breast Cancer at High Clinical but Low Genomic Risk on 70-Gene Signature Assay
In a phase III trial (MINDACT) reported in The New England Journal of Medicine, Cardoso et al found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical risk but low genomic risk as determined by the 70-gene signature assay (MammaPrint)....
Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients With NSCLC and M1a Disease?
Analysis of a large non–small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis. Findings from the study were published by Dai et al in the Journal of Thoracic Oncology. Lung cancer is...
FDA Accepts New Drug Application, Grants Priority Review of Rucaparib for the Treatment of Advanced BRCA-Mutant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has accepted Clovis Oncology’s New Drug Application (NDA) for accelerated approval of rucaparib and granted Priority Review status to the application with a Prescription Drug User Fee Act date of February 23, 2017. Rucaparib is an...
Cancer Research Institute to Honor Three Scientists for Outstanding Contributions to Cancer Immunotherapy Research
The Cancer Research Institute (CRI), a nonprofit organization established in 1953 to advance biomedical research with the goal of developing lifesaving immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields...
Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional radiotherapy in disease-free survival...
Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation
Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...
Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer
A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...
Study Finds More Nodes Should Be Examined to Rule Out Node-Negative Disease in Papillary Thyroid Cancer
The proportion of patients with papillary thyroid cancer identified as having node-negative disease decreased substantially with an increased number of lymph nodes examined, according to an analysis of data from the National Cancer Database. Robinson and colleagues, of Duke University, reported...
Pembrolizumab for Untreated/Progressive Brain Metastases in Melanoma or NSCLC
Sarah B. Goldberg, MD, of Yale University School of Medicine, and colleagues found that pembrolizumab (Keytruda) was active in untreated or progressive brain metastases in melanoma and non–small cell lung cancer (NSCLC), according to a single-center phase II trial reported in The Lancet Oncology....
Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer
Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...
Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy
Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib...
Nivolumab in Recurrent Small Cell Lung Cancer
In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the SCLC...
